Reading through premature stop codons with PTC1 24. Project Catalyst to find more Duchenne drugs. Interview by Guenter Scheuerbrandt. - Suppr | 超能文献

Reading through premature stop codons with PTC1 24. Project Catalyst to find more Duchenne drugs. Interview by Guenter Scheuerbrandt.

作者信息

Welch Ellen, Goetz Diane, Almstead Neil

出版信息

Acta Myol. 2008 Oct;27:63-8.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Reading through premature stop codons with PTC1 24. Project Catalyst to find more Duchenne drugs. Interview by Guenter Scheuerbrandt.

Acta Myol. 2008 Oct;27:63-8.

2

[Duchenne muscular dystrophy].杜兴氏肌营养不良症

MMW Fortschr Med. 2015 Jul 23;157(13):81. doi: 10.1007/s15006-015-3369-7.

3

Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).杜氏/贝克型肌营养不良症中抑制无义突变的通读策略：氨基糖苷类药物和阿他芦醇（PTC124）

J Child Neurol. 2010 Sep;25(9):1158-64. doi: 10.1177/0883073810371129. Epub 2010 Jun 2.

4

Exon skipping, a therapy for Duchenne muscular dystrophy. Interview by Guenter Scheuerbrandt.外显子跳跃疗法，一种用于杜氏肌营养不良症的治疗方法。古恩特·朔伊布兰特访谈。

Acta Myol. 2008 Oct;27:69-73.

5

The functional mechanisms and clinical application of read-through drugs.通读药物的作用机制及临床应用

Yi Chuan. 2016 Jul 20;38(7):623-633. doi: 10.16288/j.yczz.15-519.

6

Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.依伐卡托（PTC124）可诱导无义突变型囊性纤维化患儿的囊性纤维化跨膜电导调节蛋白表达和功能。

Am J Respir Crit Care Med. 2010 Nov 15;182(10):1262-72. doi: 10.1164/rccm.201001-0137OC. Epub 2010 Jul 9.

7

Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy.氨基糖苷类诱导的终止密码子通读的序列特异性：对杜氏肌营养不良症治疗的潜在意义。

Ann Neurol. 2000 Aug;48(2):164-9.

8

PTC124, nonsense mutations and Duchenne muscular dystrophy.PTC124、无义突变与杜氏肌营养不良症

Neuromuscul Disord. 2007 Oct;17(9-10):719-20. doi: 10.1016/j.nmd.2007.07.001.

9

European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene.欧洲药品管理局对阿他芦醇用于治疗5岁及以上因肌营养不良蛋白基因无义突变导致的杜氏肌营养不良门诊患者的审评。

Neuromuscul Disord. 2015 Jan;25(1):5-13. doi: 10.1016/j.nmd.2014.11.011. Epub 2014 Nov 24.

10

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.PTC124治疗由无义突变引起的囊性纤维化的疗效：一项前瞻性II期试验。

Lancet. 2008 Aug 30;372(9640):719-27. doi: 10.1016/S0140-6736(08)61168-X. Epub 2008 Aug 20.

引用本文的文献

1

Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agents.用于治疗杜氏肌营养不良症的新型化合物：新兴治疗药物。

Appl Clin Genet. 2011 Mar 10;4:29-44. doi: 10.2147/TACG.S8762. Print 2011.